Y mAbs Therapeutics (YMAB) - Total Assets
Based on the latest financial reports, Y mAbs Therapeutics (YMAB) holds total assets worth $117.21 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Y mAbs Therapeutics - Total Assets Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's total assets have evolved over time, based on quarterly financial data. Also see Y mAbs Therapeutics stock valuation for the company's overall valuation and market capitalisation.
Y mAbs Therapeutics - Asset Composition Analysis
Current Asset Composition (December 2024)
Y mAbs Therapeutics's total assets of $117.21 Million consist of 82.2% current assets and 17.8% non-current assets. Review YMAB liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.1% |
| Accounts Receivable | $19.69 Million | 16.4% |
| Inventory | $7.21 Million | 6.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.28 Million | 1.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Y mAbs Therapeutics share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Y mAbs Therapeutics's current assets represent 82.2% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 56.1% of total assets in 2024, down from 97.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 16.4% of total assets.
Y mAbs Therapeutics Competitors by Total Assets
Key competitors of Y mAbs Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Y mAbs Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.00 | 2.92 | 6.74 |
| Quick Ratio | 3.58 | 2.72 | 6.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.84 Million | $83.29 Million | $113.43 Million |
Y mAbs Therapeutics - Advanced Valuation Insights
This section examines the relationship between Y mAbs Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.47 |
| Latest Market Cap to Assets Ratio | 3.26 |
| Asset Growth Rate (YoY) | -6.2% |
| Total Assets | $119.90 Million |
| Market Capitalization | $391.22 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Y mAbs Therapeutics's assets at a significant premium (3.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Y mAbs Therapeutics's assets decreased by 6.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Y mAbs Therapeutics (2016–2024)
The table below shows the annual total assets of Y mAbs Therapeutics from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $119.90 Million | -6.23% |
| 2023-12-31 | $127.87 Million | -9.61% |
| 2022-12-31 | $141.46 Million | -33.52% |
| 2021-12-31 | $212.78 Million | +61.14% |
| 2020-12-31 | $132.05 Million | -38.97% |
| 2019-12-31 | $216.37 Million | +42.42% |
| 2018-12-31 | $151.92 Million | +64.91% |
| 2017-12-31 | $92.13 Million | +433.73% |
| 2016-12-31 | $17.26 Million | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more